Navigation Links
Vertos Medical, Inc. Appoints James M. Corbett Chief Executive Officer
Date:11/7/2008

Corbett and Daniel A. Pelak Join Board of Directors in Preparation for Launch of MILD(TM), an Innovative, Minimally Invasive Spinal Treatment

Procedure

SAN JOSE, Calif., Nov. 7 /PRNewswire/ -- Vertos Medical, Inc., a privately held medical device manufacturer focusing on a minimally invasive treatment for Lumbar Spinal Stenosis (LSS), today announced that the company has appointed James M. Corbett as its President and Chief Executive Officer and to its Board of Directors. In addition, the company announced it has expanded its Board to include Daniel A. Pelak. Corbett and Pelak bring decades of senior management experience in the development and commercialization of innovative medical devices. Vertos Medical, which has U.S. Food and Drug Administration (FDA) clearance for its MILD(TM) (Minimally Invasive Lumbar Decompression) technology, recently initiated an Institutional Review Board - controlled clinical trial called the Vertos MILD(TM) Preliminary Patient Evaluation Study.

The MILD(TM) procedure is a simple, percutaneous, fluoroscopically guided treatment for Lumbar Spinal Stenosis (LSS). MILD(TM) can be performed under local anesthesia and substantially reduces the tissue damage and removal associated with other minimally invasive or open surgeries. Recent clinical results in 32 patients(1) with moderate-to-severe LSS demonstrated improved mobility and decreased pain. To date, more than 80 patients have undergone the procedure without any adverse events.

In July 2008, Vertos completed a $12 million financing from leading venture capital firms CHL Medical Partners, Foundation Medical Partners, Aweida Ventures, and DFJ Mercury. With the addition of Mr. Corbett and Mr. Pelak, the Vertos Board expands to six members.

"We are delighted by the addition of these two seasoned executives to the Vertos Medical team. Jim has a proven track record in the medical device industry and brings demonstrated entrepreneurial leadership to Vertos as we prepare for the commercial rollout of the MILD(TM) procedure. In addition, we are pleased to have an executive with Dan's accomplishments and broad range of experience join our Board," said Myles Greenberg, M.D., Partner with CHL Medical Partners and Vertos Board member.

Mr. Corbett has more than 28 years of leadership experience in the medical device field. Most recently, he was Chief Executive Officer of ev3 Inc. (Nasdaq: EVVV), where he led the development of ev3's peripheral and neurovascular device business. Over the course of his career, Mr. Corbett has held the positions of Chief Executive Officer, Home Diagnostics Inc.; President, Boston Scientific International; and General Manager Baxter, Japan, as well as a number of executive roles in his 11 years at Baxter Healthcare.

Mr. Pelak has extensive medical device industry management experience, with a successful track record in growing young companies and productive corporate operating divisions. Until recently, he was the Chief Executive Officer at InnerPulse, a privately held, early-stage cardiac medical device company. Previously, he was the Chief Executive Officer of Closure Medical Corporation until its acquisition by Johnson & Johnson in 2005. He began his career at Medtronic, Inc., where he spent more than two decades and held the positions of Vice President of Cardiovascular Marketing, as well as Vice President and General Manager of three operating divisions.

About Vertos Medical, Inc.

Vertos is a San Jose, CA, based medical device company founded in 2005 which has recently begun commercializing an innovative, percutaneous treatment for lumbar spinal stenosis (LSS). LSS is a painful and debilitating condition diagnosed in more than 1.5 million people each year in the U.S. The Vertos MILD(TM) (Minimally Invasive Lumbar Decompression) procedure can be performed under local anesthesia and substantially reduces the tissue damage associated with other minimally invasive or open surgeries. Vertos has obtained FDA clearance for commercialization of the MILD(TM) devices in the U.S.

(1) Spine Technology Education Group, Innovative Techniques in Spine Surgery, June 18-21, 2008, Los Cabos, Mexico: 90% decrease in pain as measured by the Visual Analog Scale (VAS), as well as improved mobility, represented by a decrease in the Oswestry Disability Index (ODI) of 84%. No complications or adverse events reported. All patients discontinued the use of narcotics or pain medication at 6 weeks following the MILD procedure.


'/>"/>
SOURCE Vertos Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vertos Medical Inc. Completes Series C Financing
2. Vertos Medical Inc. Presents Clinical Data of its MILD™ Procedure at the 5th Annual Innovative Techniques in Spine Surgery Conference in Los Cabos, Mexico
3. Interview with Dr. Elisabeth Hager, CEO of Balan Biomedical, Inc., to Air Nationally on Sky Radio
4. Nonin Medical, Inc. Showcases the First Pulse Oximeter Pre-Certified by the Continua Health Alliance
5. China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
6. China Sky One Medical, Inc. Acquires Drug to Treat Breast Lesions
7. China Sky One Medical, Inc. Receives Tax Refund
8. CSA Medical, Inc. Appoints President
9. Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety
10. China Sky One Medical, Inc. Signs Distribution Agreement with Harbin Baolong Pharmaceutical Company
11. Hamilton Medical, Inc. Welcomes New Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2017)... Edmonton, AB (PRWEB) , ... July 21, 2017 , ... ... a life insurance brokerage firm servicing Albertans,” says owner and licensed broker Nerissa McNaughton. ... health insurance can be difficult, but it is a very necessary conversation. I make ...
(Date:7/21/2017)... ... , ... "As a doctor of lung medicine managing chest diseases for more ... said an inventor from Center Valley, Pa. "My idea is to improve the device ... the patent-pending PLEURAL SAFE-t-STAT CATHETER KIT to offer an efficient means of draining pleural ...
(Date:7/21/2017)... Augusta, GA (PRWEB) , ... July 21, 2017 , ... ... is teaming up with the Epilepsy Foundation in a community wide charity event with ... region. , Delaney Sunde, a young local woman who lives with epilepsy, recently launched ...
(Date:7/21/2017)... Minnesota (PRWEB) , ... July 21, 2017 , ... ... BWBR recently were selected to renovate and improve the Ramsey County Medical Examiners ... adjacent to Regions Hospital, the $2.5 million project is scheduled to start in ...
(Date:7/21/2017)... ... July 21, 2017 , ... Hospital M&A activity slowed in the second quarter ... hospital acquisitions rose to 23 in the second quarter, up 15% from the 20 ... 20 announced deals in the year-ago second quarter. Only four of the transactions disclosed ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
(Date:6/30/2017)... SAN DIEGO , June 30, 2017  AVACEN Medical (AVACEN) ... Access Journal. The research describes the use of its AVACEN ... by those suffering from fibromyalgia. ... AVACEN Medical ... Fibromyalgia is characterized by chronic widespread pain. It affects approximately 200 to ...
(Date:6/27/2017)... 27, 2017   NuEyes (NuEyes Technologies Inc.) today ... fuel its growth in helping the legally blind live more ... Group), the leading developer of augmented, virtual and mixed reality ... The undisclosed funding amount was provided by strategic partners ... with offices in Abu Dhabi , ...
Breaking Medicine Technology: